Seer, Inc. SEER

Company Overview

Seer, Inc. is a U.S.-based life sciences company focused on proteomics, the large-scale study of proteins and their role in biological systems. The company develops technologies intended to enable researchers and biopharmaceutical companies to perform unbiased, deep, and scalable proteomic analysis. Seer primarily operates within the biotechnology tools and life sciences instrumentation industries, with a business model centered on instrument platform adoption, consumable sales, and related research collaborations. Its core offerings include the Proteograph Product Suite, which combines engineered nanoparticles, automation workflows, and software analytics designed to improve protein detection across complex biological samples.

The company was founded in 2017 and is headquartered in Redwood City, California. Seer emerged from research involving nanoparticle engineering and proteomic analysis technologies developed to address limitations in traditional mass spectrometry workflows. Since its initial public offering in 2020, the company has focused on expanding commercial adoption among academic research institutions, pharmaceutical companies, and translational medicine organizations. Seer’s strategic positioning is based on enabling broader and deeper proteomic insights at scale, particularly for biomarker discovery, precision medicine research, and systems biology applications.